Audio is streamed directly from the publisher (mcdn.podbean.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
Transcription factors control the genetic programs that maintain cellular balance, but while they have been seen as compelling targets for aging-related disease, they have long been considered “undruggable.” Junevity’s RESET platform leverages large-scale human omics data and AI models to pinpoint key transcriptional drivers of disease and to design siRNA therapies that restore healthy gene expression. We spoke to John Hoekman, co-founder and CEO of Junevity, about the role of transcription factors in healthy biology and aging-related disease, the company’s AI-driven platform for identifying dysregulated transcription factors, and its lead programs targeting type 2 diabetes and obesity.